Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioNanomatrix LLC

This article was originally published in Start Up

Executive Summary

BioNanomatrix envisions multiple potential applications for its NANOANALYZER benchtop-sized molecular optical imager capable of scanning single molecules. DNA sequencing is one--the company thinks its technology's ability to deliver single molecule sensitivity in a highly parallel format with minimal processing will provide a fast, low cost solution.

You may also be interested in...



Next-generation Sequencing: Slowly Moving towards the $1,000 Genome

Even if most attempts to read DNA strands in real time appear stalled and the goal of true single-molecule sequencing has, with the notable exception of Helicos, for the most part given way (at least for the time being) in favor of cluster-based approaches with lower data densities, there's still plenty of opportunity for start-ups to advance the field of next-generation sequencing: with microfluidics, nanotechnology, and biochemistries to better enable direct DNA observation and analysis.

Biodesy LLC

Second-harmonic generation is an optical phenomenon that occurs when a nonlinear surface combines photons of light to produce photons with twice the frequency and half the wavelength of the original photons. Biodesy is harnessing its power to measure protein conformation for drug discovery.

Jenken Biosciences Inc.

At present, there are no approved small molecule anti-inflammatory drugs for treating hepatitis C. Indeed, most drug R&D activity for hepatitis centers on new or improved anti-viral therapy rather than complications of the infection, e.g., the chronic inflammation that occurs in 80% of hepatitis cases. Jenken Biosciences hopes to change that. Jenken is repurposing two different, chemically similar, marketed compounds for new indications associated with chronic organ inflammation.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC091199

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel